Cost-utility analysis of screening for diabetic retinopathy in Japan: A probabilistic Markov modeling study

Ophthalmic Epidemiology

Volumn 22, Issue 1, 2015, Pages 4-12

  Kawasaki, Ryo ^a   Akune, Yoko ^b   Hiratsuka, Yoshimune ^c   Fukuhara, Shunichi ^d   Yamada, Masakazu ^b,e  

^a YAMAGATA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cost utility analysis; Diabetic retinopathy; Japan; Markov model; Screening

Indexed keywords

VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; BLINDNESS; CLINICAL STUDY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; HEALTH CARE COST; HUMAN; INCIDENCE; JAPAN; JAPANESE (PEOPLE); LASER COAGULATION; MACULAR EDEMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POPULATION SIZE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SIMULATION; VISION; VITRECTOMY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH SERVICES RESEARCH; MALE; MIDDLE AGED; PROBABILITY; STATISTICAL MODEL; VERY ELDERLY; VISION TEST;

ADULT; AGED; AGED, 80 AND OVER; BLINDNESS; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; JAPAN; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; VISION SCREENING;

EID: 84920829461     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.3109/09286586.2014.988876     Document Type: Article

References (36)

1. Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: a review. Clin Experiment Ophthalmol 2012;40:27-38.
2. Fenwick EK, Pesudovs K, Rees G, et al. The impact of diabetic retinopathy: understanding the patient's perspective. Br J Ophthalmol 2011;95:774-782.
3. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564.
4. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Internal Med 2014;160:18-29.
5. Kinukawa J, Shimura M, Harata N, Tamai M. Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocininduced diabetes. Curr Eye Res 2005;30:789-798.
6. Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol 2011;129:435-444.
7. Ministry of Health, Labour and Welfare, Japan. The National Health and Nutrition Survey in Japan, 2009. 2011.
8. Oizumi T. [Epidemiologic investigation on the incidence of diabetes mellitus from impaired glucose tolerance in population based study]. Nihon Rinsho 2005;63(Suppl. 2):73-77.
9. Miyazaki M, Kubo M, Kiyohara Y, et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study. Diabetologia 2004;47:1411-1415.
10. Ministry of Health, Labour and Welfare, Japan. Implementation rate of specific health checkup and specific counseling guidance for 2009 in Japan; 2011. Accessed July 30, 2013 from: www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/info03-h21.html.
11. Ministry of Health Labour and Welfare, Japan. National Health and Nutrition Survey for 2002 in Japan; 2002. Accessed July 30, 2013 from: www.mhlw.go.jp/toukei/kouhyo/indexkk-4-2.html.
12. OECD. Health at a Glance 2007: OECD Indicators. Paris: OECD Publishing. 2007.
13. Holden BA, Fricke TR, Ho SM, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol 2008;126:1731-1739.
14. Funatsu H. Status of ophthalmological examination in diabetics. [In Japanese]. Folia Ophthalmologica Japonica 1997;48:7-13.
15. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
17. Yamamoto T, Hitani K, Tsukahara I, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 2003;135:14-19.
18. Sakamoto T, Hida T, Tano Y, et al. [Survey of triamcinolone acetonide for ocular diseases in Japan]. Nihon Ganka Gakkai Zasshi 2007;111:936-945.
19. Yamakiri K, Sakamoto T, Noda Y, et al. Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy. Ophthalmology 2007;114:289-296.
20. Chew EY, Ferris III FL, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110:1683-1689.
21. Nakamura S, Funatsu H, Yagi T, et al. Five-year outcome of retinal photocoagulation in patients with diabetic retinopathy. [In Japanese]. Folia Ophthalmol Jpn 2003;54:329-333.
22. Yoshida S, Matsumoto T, Nabeshima T, et al. A two-year review of vitreous surgery for proliferative diabetic retinopathy. Jpn J Clin Ophthalmol 2010;64:1911-1915.
23. Hiratsuka Y, Yamada M, Murakami A, et al. Cost-effectiveness of cataract surgery in Japan. Jpn J Ophthalmol 2011;55:333-342.
24. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511.
25. Mulvaney-Day NE, Horvitz-Lennon M, Chen CN, et al. Valuing health in a racially and ethnically diverse community sample: an analysis using the valuation metrics of money and time. Qual Life Res 2010;19:1529-1540.
26. Szabo SM, Beusterien KM, Pleil AM, et al. Patient preferences for diabetic retinopathy health states. Invest Ophthalmol Vis Sci 2010;51:3387-3394.
27. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;319:635-638.
28. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3:1-134.
29. Ministry of Health, Labour and Welfare, Japan. Survey of medical care activities in public health insurance. 2010.
30. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-437.
31. A basic direction for comprehensive implementation of national health promotion 2012. Accessed June 4, 2014 from: http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000047330.pdf.
32. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889-896.
33. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010;27:249-256.
34. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-384.
35. Brown MM, Brown GC, Sharma S. Evidence-based to value-based medicine. Chicago: American Medical Association Press; 2005.
36. Sharma S, Brown GC, Brown MM, et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002;86:493-496.